Revisiting: Melanocortin agonists: mechanism and the documented adverse profile posts 121–142

AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.

I would be interested in a counterexample if anyone has one.

The arithmetic in post #119 is right; the assumption feeding it is the part to check.

What I can speak to on Melanocortin agonists is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.

Where I part company with post #119, and it is a narrow parting.

On Melanocortin agonists I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Reporting rather than recommending, on Melanocortin agonists. What happened is above. Whether it should have is a different question and not one I am qualified to answer.

Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a solubility profile and the supplier should state it.

I had written a reply contradicting post #123 and deleted it. Here is what survived.

Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.

That is one dataset and I would not build a rule on it.

I read the earlier replies on Melanocortin agonists twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.

Post #130 answers the question as asked. The question underneath it is different.

Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.

Posting it because the silence on this was starting to look like agreement.

Melanotan II is a non-selective melanocortin agonist, which is why its effects are not confined to pigmentation. The non-selectivity is the mechanism and not a side issue.

What I would tell a new member reading about Melanocortin agonists for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.

Quietly grateful for the plain phrasing. Not every thread gets that.